https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-09844&r=1
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors - NCI
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-iii-study-of-silmitasertib-in-children-and-young-adults-with-relapsed-refractory-solid-tumors-302297569.html?
Senhwa Biosciences announces first patient dosed in the Phase I/II study of Silmitasertib in...
/PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases,...